Luqa Pharmaceuticals and Stratpharma enter into an exclusive agreement

Luqa Pharmaceuticals announced today that it has entered into an exclusive agreement with Stratpharma AG of Switzerland to promote, sell, and distribute Strataderm®, in the People's Republic of China.

Strataderm is already approved in China, where launch preparations are being initiated. Luqa's roll-out to hospital and retail will start during Q4 2012.

Strataderm is a rapidly drying, non-sticky, transparent, silicone gel formulation for the treatment of scars, both old and new. Strataderm has been developed using a new silicone polymer technology that is self drying without the use of Silicone Dioxide. Silicone gel is the only non-invasive scar treatment option for which evidence based recommendations have been made. The International Clinical Recommendations on Scar Management stated "silicone gel should be used as first line therapy in the initial management of scars and in the prevention of hypertrophic scars and keloids."(1)

Up to 94% of Chinese patients develop hypertrophic scars following median sternotomy incision and 41% of women develop a hypertrophic scar within 12 weeks of caesarean delivery. Few clinically proven alternatives for scar therapy are currently available in China.

"It is exciting to further expand the international commercial availability of Strataderm® through this partnership with Luqa in China. This partnership will ensure Strataderm becomes available sooner and to more patients than otherwise possible in the Chinese market." said Darren Kerr, the CEO of Stratpharma.

"The addition of a ready to market leading scar treatment like Strataderm® to our portfolio provides Luqa with the ability to expand one of our strategic therapeutic areas and to accelerate our plans for product commercialization in China while brigning innovation to patients and physicians," stated Robert Braithwaite, Luqa's CEO.

About Luqa Pharmaceuticals
Luqa Pharmaceuticals is a China-based specialty pharmaceutical company with operations across Asia. We dedicate our talent to build a best in class portfolio of innovative products to meet the medical needs of the markets we work in. We are experts and are passionate about bringing products to market in record time, enhancing market access and commercialization excellence. Luqa's entrepreneurial culture combines international best practices and know-how with comprehensive, fast and flexible local strategies.

About Stratpharma
Stratpharma specialises both in the development and in the licensing and global commercialisation of novel medical devices and pharmaceutical products. Stratpharma's dermatology team has many years of international experience in the dermatological therapeutic franchise with a current focus on scars and wounds. These products for scar management and abnormal scar prevention can be used alone or in combination with other more invasive therapies. The current products including Strataderm® are registered and are available in over 50 countries in Europe, North America and Asia.

1. Mustoe, T.A. et al.: "International Clinical Recommendations on Scar Management", Plastic and Reconstructive Surgery 2002; 110:560–571

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...